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Abstract 
Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for the selec-
tion of metastatic colorectal cancer (mCRC) patients eligible for the therapy with anti-EGFR monoclonal antibodies. 
The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytology (SIAPEC) organ-
ized an external quality assessment (EQA) scheme for CRC to evaluate inter-laboratory consistency and to ensure 
standardization of the results in the transition from KRAS to all-RAS testing.
Methods: Ten formalin fixed paraffin embedded specimens including KRAS/NRAS (exons 2, 3, 4) and BRAF (codon 
600) mutations were validated by three referral laboratories and sent to 88 participant centers. Molecular pathology 
sample reports were also requested to each laboratory. A board of assessors from AIOM and SIAPEC evaluated the 
results according to a predefined scoring system. The scheme was composed of two rounds.
Results: In the first round 36 % of the 88 participants failed, with 23 centers having at least one false positive or false 
negative while 9 centers did not meet the deadline. The genotyping error rate was higher when Sanger sequencing 
was employed for testing as compared with pyrosequencing (3 vs 1.3 %; p = 0.01; Pearson Chi Square test). In the 
second round, the laboratories improved their performance, with 23/32 laboratories passing the round. Overall, 79/88 
participants passed the RAS EQA scheme. Standardized Human Genome Variation Society nomenclature was incor-
rectly used to describe the mutations identified and relevant variations were noticed in the genotype specification.
Conclusion: The results of the Italian RAS EQA scheme indicate that the mutational analyses are performed with 
good quality in many Italian centers, although significant differences in the methods used were highlighted. The rela-
tively high number of centers failing the first round underlines the fundamental role in continued education covered 
by EQA schemes.
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Background
Cetuximab and panitumumab are two monoclonal anti-
bodies (mAbs) that bind the extracellular domain of the 
EGFR, block its interaction with ligands and inhibit its 
downstream signalling [1, 2]. These drugs were initially 
proved to be effective only in a subgroup of metastatic 
colorectal cancer (mCRC) carrying a wild-type KRAS 
gene in codons 12 and 13 of exon 2 [3–5] and in 2009 
received the European Medicines Agency (EMA) 
approval for this molecularly selected group of mCRC 
patients. Exon 2 KRAS mutations are usually detected 
in approximately 30–40 % of CRC patients, representing 
up to 90 % of all KRAS mutations [5]. More recently, less 
frequent mutations in exon 3 and 4 of KRAS and muta-
tions in exons 2, 3 and 4 in NRAS have been demon-
strated to be equally associated with resistance to EGFR 
monoclonal antibodies [6–8]. Although RAS mutations 
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are an early event in colon tumorigenesis, heterogene-
ous expression of RAS variants in CRC has been recently 
reported [9].
On the basis of these studies, in 2014 the EMA 
restricted the use of cetuximab and panitumumab to 
patients with RAS (exon 2, 3 and 4 of KRAS and NRAS 
genes) wild-type status. Following this updating, KRAS 
and NRAS testing has become a fundamental part in the 
decision-making process for the identification of the cor-
rect pharmacological approach to mCRC. Other genes 
involved in EGFR downstream pathways, such as BRAF, 
PIK3CA and PTEN, might be involved in the develop-
ment of resistance mechanisms to cetuximab and pani-
tumumab in CRC, although their role is not completely 
clarified [10–12]. Despite this controversial position, 
the analysis of the mutational status of BRAF is often 
required by the oncologists, since it is a strong nega-
tive prognostic biomarker for mCRC patients and BRAF 
mutant patients are often treated with aggressive thera-
peutic regimens.
RAS and BRAF molecular tests must produce accurate, 
reliable and readily available results, since they directly 
influence treatment decisions. Up to date, many dif-
ferent testing methods exist and no further indications 
have been provided by the EMA on which test is the 
most reliable. Moreover, the complexity of the analyses 
required is increasing with the identification of new pre-
dictive biomarkers and the development of new precision 
drugs. For all these reasons, today the External Quality 
Assessment (EQA) of the laboratories performing these 
analyses is considered an essential step to ensure inter-
laboratory consistency and to obtain the harmonization 
and standardization of the results. In 2013, AIOM and 
SIAPEC-IAP organized the EQA scheme for CRC includ-
ing the analysis of BRAF exon 15 mutations in codon 600, 
in addition to exon 2, 3 and 4 of KRAS and NRAS genes. 
This article summarizes the results obtained during the 
scheme and evaluates shortcomings in both genotyping 




Formalin fixed paraffin embedded (FFPE) specimens 
derived from resected mCRC were collected at refer-
ral surgical pathology departments. One 10-µm-thick 
slide derived from samples with an adequate content of 
tumor cells (≥50 %) was selected and analysed by three 
referral centers that were selected based on their expe-
rience in molecular pathology, their track of scientific 
publications and their expertise in EQA organization: 
the Center of Predictive Molecular Medicine at CeSI Bio-
tech in Chieti, the Department of Human Pathology and 
Oncology at the University of Florence and the Labora-
tory of Pharmacogenomics, at CROM—INT “Fondazi-
one Giovanni Pascale” in Mercogliano. Three different 
methods in a blinded fashion were used (pyrosequencing, 
Ion AmpliSeq™ Colon and Lung Cancer panel—Thermo 
Fisher Scientific©, Sanger sequencing). Among the sam-
ples analysed, 20 were chosen for which a 100  % con-
cordance between the referral centers was obtained and 
a percentage of mutant allele  >15  % was observed. The 
percentage of mutant allele in each sample used in first 
and in second round was quantified using the Ion Tor-
rent™ panel. For each sample, the thirtieth, the sixtieth 
and the last section obtained from the block were rean-
alysed for KRAS, NRAS and BRAF mutational status by 
using pyrosequencing, to ensure that the mutation was 
homogeneously present within the block.
The same samples were sent to all participating labo-
ratories. Due to the high number of participants, the 
scheme focused on the mutational analysis only, because 
it was not feasible to provide sections for pathological 
review that will be addressed in a dedicated program.
Registration of the participants and shipment of the 
samples
Laboratories that performed the analyses of all the three 
genes were invited to participate to the EQA. The cent-
ers could register at the http://www.rasquality.it web site 
and were asked to extract DNA and perform the analyses 
by using their routine methods. In each round, one slide 
of 10-µm thickness for each of the 10 samples was sent 
to the laboratories which correctly registered on the web 
site. Each specimen was given a random code automati-
cally created by an application of the web site, to avoid 
exchange of information among the centers and to univo-
cally identify the samples. The deadline for inserting the 
results on the web site was set 3 weeks after the shipment 
date. The laboratories were also asked to provide infor-
mation on the methods used to perform the mutational 
analyses. A molecular pathology sample report, uploaded 
and sent together with the results, was requested to each 
laboratory and was used only for a qualitative evaluation.
Evaluation of the results
The EQA scheme consisted of two consecutive rounds: 
the centers that failed the first round had the chance 
to register for a second round and were provided with 
another set of 10 samples. A board of assessors from 
AIOM and SIAPEC evaluated the results according to a 
predefined scoring system, in accordance with the Euro-
pean guidelines (Table 1) [13].
In order to pass the scheme, the AIOM-SIAPEC board 
established that both a score  ≥18 and the absence of 
false positive or negative results are compulsory, since 
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a serious genotyping error can adversely influence the 
identification of the correct therapeutic approach.
The participating laboratories received a report with 
the detailed results of each round. In particular, for each 
sample, the score and a comment to explain the errors 
were indicated.
Results
Selection of the samples for the EQA scheme
The EQA scheme was composed of two rounds, the sec-
ond one open only to those centers which failed the first 
round. FFPE specimens with an adequate tumor cell con-
tent (≥50  %) were selected following analysis in three 
referral centers. Of the samples sent both for the first and 
the second round, 5 were wild-type for exons 2, 3 and 4 
of KRAS and NRAS genes and for exon 15 of BRAF gene, 
while each of the other 5 samples had a mutation either 
in KRAS or in NRAS or in BRAF (Table 2).
Overall, during the EQA 1200 samples were shipped 
and 1070 samples were effectively analysed (790 in the 
first and 280 in the second round). Testing was manda-
tory for exons 2, 3 and 4 of both KRAS and NRAS and for 
the BRAF V600E mutation.
First round
Ninety centers registered on the web site http://www.ras-
quality.it, 4 of which from foreign countries. Two labora-
tories withdrew and 88 participated in the first round of 
the EQA. The participants were given 3 weeks to submit 
the results and 9 centers out of 88 were not able to fulfil 
this term. Thus, the results were obtained for 790 out of 
880 shipped samples.
Analytical errors were observed in 41 of the 790 sam-
ples analysed (5.2 %), of which 17 (41.5 %) resulted to be 
false positives (3 laboratories with 2 false positives each), 
and 15 false negatives (36.6  %), with 2 centers having 2 
false negatives each. In 8 cases (19.5  %) false negative 
and positive results occurred simultaneously in the same 
sample: for example, a sample that was mutated for KRAS 
and wild type for NRAS and BRAF but was incorrectly 
reported as KRAS and NRAS wild type and mutated for 
BRAF, was scored as false negative in KRAS and false 
Table 1 Scoring system
a Deduction applied only once
Criteria Marks
Correct genotype 2.00
Error in the nomenclature that might lead to misinterpretation  
of the results
1.5a
Genotype mispositioned or miscalled (partially correct diagnosis) 1
Test failure living no result on the sample 0.5
Incorrect genotype (false negative or false positive) 0
Table 2 Mutational status of the samples selected for the first (A-label) and the second (B-label) round of the EQA
a In parentheses it is indicated the percentage of allele frequency evaluated by means of Ion Torrent
Sample ID KRASa BRAFa NRASa
A1 WT WT WT
A2 WT WT WT
A3 WT WT WT
A4 WT WT WT
A5 WT WT WT
A6 WT p.V600E (c.1799T > A) (27.6 %) WT
A7 p.A146T (c.436G > A) (27.6 %) WT WT
A8 p.G12D (c.35G > A) (24.2 %) WT WT
A9 WT WT p.G12D (c.35G > A) (18.1 %)
A10 WT WT p.Q61K (c.181C > A) (74.6 %)
B1 WT WT WT
B2 WT WT WT
B3 WT WT WT
B4 WT WT WT
B5 WT WT WT
B6 p.G12D (c.35G > A) (27.7 %) WT WT
B7 p.A146T (c.436G > A) (62 %) WT WT
B8 WT WT p.Q61R (c.182A > G) (29.5 %)
B9 WT WT p.G12S (c.34G > A) (45.2 %)
B10 WT p.V600E (c.1799T > A) (36.9 %) WT
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positive in BRAF. In one sample (2.4 %) the genotype was 
mispositioned.
The most used methods were pyrosequencing and 
Sanger sequencing while real-time PCR was the third 
most used approach, with a relevant gap between 
the number of centers that used sequencing-based 
approaches or real-time PCR (Fig.  1). Given that each 
sample was analyzed for KRAS, NRAS and BRAF, the 
total number of tests performed by means of pyrose-
quencing or Sanger sequencing were 1068 and 831, 
respectively. The results of the analyses performed with 
these two approaches were compared by Pearson Chi 
Square test. A significantly higher incidence of errors was 
detected in those cases where Sanger sequencing was 
chosen, in particular, in 25 analyses out of 831 (3 %). In 
contrast, the percentage of error decreased when pyrose-
quencing (14 errors out of 1068; 1.3 %) was used (p value 
0.01) (Fig. 1). Efficiency of the other methods could not 
be evaluated since they were underrepresented.
As shown in Table 3, the higher genotyping score was 
obtained for sample A8 carrying a KRAS p.G12D muta-
tion, while the lowest was obtained for samples A7 
(KRAS p.A146T) and A10 (NRAS p.Q61K).
Twenty-two (27.8 %) laboratories of the 79 that eventu-
ally sent the results obtained the maximum score of 20 
points. The score of 18 was obtained by 5 centers, but 
all of them made one genotyping error, thus failing the 
round. Only one center had a very poor performance, 
with a score of 9 points, but the laboratory retrospectively 
declared to have analysed only KRAS exon 2; the labora-
tory was automatically included in the second round.
Among the 88 centers that took part in the EQA, 56 
(64  %) obtained a score  >18 and passed the EQA. The 
remaining 32 laboratories were enrolled in the second 
round, including 3 foreign centers that did not pass the 
first round.
Second round
In the second round, another set of 10 samples was 
sent to the 32 participating laboratories approximately 

















0 0 1 
2 2 





Fig. 1 List of the methodologies used in the RAS EQA and relative errors. The blue bar indicates the number of centers that used the related 
method; the red bar indicates the absolute number of errors on the total of analyses performed with the indicated method
Table 3 Score per case of the samples analysed in the first 
round
a Not considering nomenclature errors






A6 BRAF p.V600E 1.83
A7 KRAS p.A146T 1.56
A8 KRAS p.G12D 1.92
A9 NRAS p.G12D 1.81
A10 NRAS p.Q61K 1.67
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Twenty-eight laboratories submitted the results within 
the 3-week deadline, for a total number of 280 results 
inserted on the website.
On the whole, 10 (3.5  %) errors were reported (false 
positives: 3, 30 %; false negatives: 2, 20 %, both false posi-
tive and negative results: 1, 10  %; mispositioned geno-
type: 4, 40 %). Among the 28 centers that submitted the 
results, 23 passed the second round, while 5 made at 
least one error. Of the 3 foreign laboratories that par-
ticipated to the second round, only one had a score ≥18 
and no major genotyping error. Overall, the laboratories 
improved their performance, with 20/32 centers (62.5 %) 
getting the maximum score and 23 laboratories (71.8 %) 
passing the round. Among the 5 centers that made errors, 
except for one laboratory that had not submitted the 
results within the deadline in the first round, the remain-
ing 4 centers improved their performances, although 
obtaining a score <18.
Eventually, 79 of 88 participants obtained a score ≥18 
in the first or in the second round and passed the RAS 
EQA scheme, including 2 foreign centers (Fig. 2). The list 
of the laboratories that passed the scheme is published 
on the web site of AIOM and SIAPEC (http://www.aiom.
it; http://www.siapec.it).
Clinical report evaluation
Reports were uploaded on the EQA website by all the 
participants; they were evaluated only on a qualitative 
level and no mark was given to them. The structure of 
the reports was extremely variable among the laborato-
ries, with the exception of fixed criteria which were nor-
mally indicated such as patients name, date of birth and 
test result. Relevant information such as specification of 
mutations tested, percentage of neoplastic cells, charac-
teristics of the methods used and interpretation of the 
results were at times or rarely indicated in the reports.
Significant variations were noticed in the genotype 
specification, since reference sequence was almost never 
declared and standardized Human Genome Variation 
Society nomenclature was incorrectly used to describe 
the mutations identified [14].
Discussion
The rapid development and approval of new drugs that 
target molecular features of cancer cells is leading to a 
significant improvement of personalised medicine in 
oncology. Among the compounds available for the tar-
geted therapy of CRC, cetuximab and panitumumab have 
been demonstrated to be active in RAS wild type patients. 
The AIOM and SIAPEC scientific board decided to intro-
duce also BRAF mutational analysis in the RAS EQA, 
although not recommended in the EMA guidelines, also 
to fulfil the oncologist needs, since it can provide addi-
tional information on patient’s prognosis.
The RAS EQA was focused only on the genotyping 
analysis, and not on the pre-analytical phase, in order to 
reduce inter-laboratory variability due to the steps of dis-
sections and evaluation of tumor cell content: thus it was 
possible to focus on the comparative assessment of the 
sensitivity and specificity of the methods used in the dif-
ferent laboratories [15].
As in the previous Italian EQA schemes [16, 17], the 
samples used for the tests were FFPE tissues, to ensure 
a stringent correlation with routine diagnostic activity, 
as in other European EQA [18, 19]. A total amount of 10 
samples, suggested to be the adequate number of cases 
for proficiency testing in this field [13, 19], was used both 
for the first and the second round. However, in the Italian 
EQA schemes the same tissue samples are distributed to 
all participating centers, whereas groups of 10–15 labo-
ratories on the basis of a regional distribution received 
different samples in the ESP EQA schemes [20]. In addi-
tion, EMQN uses as standards FFPE blocks containing 
cell lines. Therefore, the Italian schemes are the only to 
distribute the same tumor tissues to all participating lab-
oratories, thus rendering possible a true inter-laboratory 
comparison among all participants with samples that 
resemble the routine clinical practice.
Nine centers did not meet the three-week deadline in 
the first round and four in the second round. No justifica-
tion was provided by these centers. Because all-RAS test-
ing was implemented shortly before the start of the EQA 
in most Italian centers, lack of experience in testing and 
problems of supply of reagents might have caused this 
phenomenon.
Although after the two rounds 79 centers out of 88 
(89.8  %) passed the scheme, the error rate in the first 
round was worrying. Indeed, 36 % of the centers did not 







Fig. 2 Results of the Italian external quality assessment for all-RAS 
and BRAF testing in colorectal carcinoma
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submitted the results (29.1  %) having at least one false 
positive or false negative. These data are in line with the 
recently published results of the ESP RAS EQA showing 
a high rate of genotyping errors, although lower as com-
pared to our results (3.6 vs 5.2  % in this study) [20]. In 
this respect, it must be emphasized that in the ESP EQA 
RAS 2014, full RAS and BRAF testing were not manda-
tory and only 49.3 % of the participants had completely 
implemented the new test requirements at the time of 
samples shipment [20]. Therefore, this is the first EQA to 
report data on full RAS and BRAF testing. Interestingly, 
the lowest average scores were located in exon 4 of KRAS 
and in exon 3 of NRAS gene, whereas the error rate for 
NRAS exon 2 was similar to KRAS exon 2. The number 
of errors for the codons recently added by the EMA was 
similar in the Italian and ESP EQAs. For example, the 
genotyping error rate for NRAS exon 3 were 16.5 and 
15.4 % in the Italian and ESP EQA schemes, respectively. 
Because less than 50 % of the centers in the ESP scheme 
analysed all RAS exons, this might in part explain the 
difference in the overall error rate between the AIOM-
SIAPEC and the ESP schemes. These data underline that 
introduction of new testing requirements might lead to 
a higher error rate if adequate training is not performed. 
We have also to recognize that the samples used in this 
EQA had a relatively high frequency of mutant alleles and 
they were not challenging, although they do represent 
the average sample type that is encountered in routine 
diagnostics in CRC.
The scoring system approved by AIOM and SIAPEC 
determines the failure of laboratories that commit one 
single genotype error. In fact, false positives prevent the 
patients from obtaining an active therapy, while false nega-
tives cause the detrimental effects since they result in the 
administration of an inactive and potentially toxic com-
pound to non-responder patients. Furthermore, treatment 
of RAS mutant CRC patients with anti-EGFR mAbs plus 
oxaliplatinum-based therapy has been shown to reduce 
patients’ survival [6]. The statistical analysis revealed a 
significantly better outcome of pyrosequencing com-
pared to Sanger sequencing (Pearson Chi square p value: 
0.01). This evidence might be related both to the ability of 
pyrosequencing to sequence short fragments, that allows 
an increased performance on FFPE samples, and to the 
higher sensitivity of this method compared to sequenc-
ing (5 vs 10–20  %) [16, 21]. Indeed, in this EQA the use 
of pyrosequencing surpassed the use of Sanger sequencing 
in routine diagnostic practice. Nevertheless, many labora-
tories that used Sanger sequencing had an excellent per-
formance. This indicates that the sensitivity of the Sanger 
sequencing can vary among the different centers and it 
is also influenced by the single laboratory expertise. For 
these reasons, it would be appropriate for every laboratory 
to assess the limit of detection of the technique they cur-
rently use. The different sensitivity might account for the 
relatively high number of false negative results but opens 
the question of the number of false positive that were 
higher than false negatives in both rounds (I round: 17 vs 
15; II round: 3 vs 2). Apart from potential contamination of 
the sample, a possible explanation is represented by poten-
tial artefacts introduced by PCR or sequencing cycle, espe-
cially when a low input DNA is used for amplification. In 
this regard, a high rate of false positive has also been found 
in the AIOM-SIAPEC EQA for EGFR testing that also 
showed a higher error rate for laboratories using Sanger 
sequencing as compared to those employing pyrosequenc-
ing or Real Time PCR [17]. Overall, these data suggest that 
Sanger sequencing should be adopted by centers with high 
experience in molecular biology because it requires an 
accurate standardization of the workflow.
Once again the importance of having two rounds 
within the same year was confirmed, since the major-
ity of laboratories which had the chance to repeat the 
analyses, actually enhanced their performances, and 
surprisingly a high percentage of centers (72 %) passes 
the second round, obtaining in most cases the 100 % of 
correct answers. The fact that approximately 3 months 
passed between the two rounds might also account 
for the significant improvement in performance of the 
majority of centers. However, 9 centers did not pass the 
EQA and no consequence of poor performance is fore-
seen in the Italian health system. Nevertheless, AIOM 
and SIAPEC publish the list of the centers that did 
pass the EQA, thus allowing medical oncologists and 
patients to choose laboratories that successfully partici-
pated in the scheme. In addition, the Italian scientific 
societies offer training for centers with poor perfor-
mance in order to help them to improve their quality.
Review of clinical reports showed a number of issues, 
although they received only a qualitative evaluation. In 
the first place, the majority of laboratories included a 
number of essential elements, namely patient ID, date of 
birth, method applied and results found. On the other 
hand, several critical details were missing, such as type of 
specimen used, limit of detection of the methods applied, 
reference sequence and clinical interpretation, leading to 
ambiguous and unclear reports. Information regarding for 
example the sensitivity and method limits might be cru-
cial for the clinical interpretation of the obtained results, 
since a test that might not be able to detect all the relevant 
mutations or that is not appropriately sensitive for a chal-
lenging specimen may mislead treatment decision.
In general, the results of the II Italian RAS EQA scheme 
indicate that the mutational analyses are performed with 
good quality in many Italian centers, although a lack in uni-
formity in reporting the results was pointed out. The high 
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number of centers failing the first round underline the 
fundamental role in continued education covered by EQA 
schemes, which aim at identifying errors in methodolo-
gies and ensuring an adequate quality of molecular testing. 
Moreover, the writing of guidelines to implement the uni-
formity of analyses and of reporting both genotyping data 
and results is essential to increase high-quality performance.
Finally, the introduction of new biomarkers in the iden-
tification of the optimal pharmacological approach to 
cancer determines the continuous development of testing 
requirement. In the next future personalized medicine 
will be based on the availability of new compounds and 
the combination or the sequential use of therapies will be 
implemented to overcome resistance mechanisms. Inevi-
tably, not only the number of biomarkers to test but also 
of patients requiring molecular analyses will increase, 
further enhancing the need for reliable and constantly 
up-to-date testing services.
Conclusions
Our study has highlighted the importance of external 
quality assessment in molecular pathology to ensure that 
patients receive adequate diagnostic test for their disease. 
The high error rate of the first round emphasizes the 
need for scientific societies, regulatory authorities, man-
ufacturers of diagnostic kits and dedicated professionals 
of the field to work together to improve the overall qual-
ity and accelerate the standardization of new tests neces-
sary for patients with cancer.
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